Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Meta-analysis Of The Galad Model For Diagnosing Primary Hepatocellular Carcinoma

Meta-analysis of the GALAD model for diagnosing primary hepatocellular carcinoma

Jian-Lin Lu1,1, Xiao-Yan Yuan2,1, Jin-Shan Zhang1

  • 1Department of Radiation Oncology and Nuclear Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.

Technology and Health Care : Official Journal of the European Society for Engineering and Medicine
|May 17, 2024

Related Experiment Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

2.2K
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

1.1K

View abstract on PubMed

Summary
This summary is machine-generated.

The GALAD model demonstrates strong diagnostic accuracy for hepatocellular carcinoma (HCC), showing high sensitivity and specificity for both early and all stages. This makes it a valuable tool for screening cancer development in chronic liver disease patients.

Area of Science:

  • Hepatology
  • Oncology
  • Diagnostic Accuracy Studies

Background:

  • The GALAD (gender-age-Lens culinaris agglutinin-reactive alpha-fetoprotein-alpha-fetoprotein-des-gamma-carboxy prothrombin) logistic regression model is used for diagnosing hepatocellular carcinoma (HCC).
  • There has been a lack of high-level evidence evaluating and summarizing the diagnostic performance of the GALAD model.

Purpose of the Study:

  • To assess the diagnostic ability of the GALAD model for hepatocellular carcinoma (HCC).
  • To provide a comprehensive summary of the GALAD model's performance through a meta-analysis.

Main Methods:

  • Systematic search of multiple databases (PubMed, Embase, Web of Science, etc.) for original diagnostic studies on HCC.
  • Inclusion of 10 studies after screening based on predefined criteria.
Keywords:
HCCbiomarkersdiagnostic efficiencyearly detection of cancer

Related Experiment Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.2K
Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma
07:47

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

2.2K
Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

1.1K
  • Evaluation of methodologic quality using the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool and statistical analysis.

    • Main Results:

    • Pooled sensitivity and specificity for all-stage HCC were 0.86 (95% CI: 0.82, 0.90) and 0.90 (95% CI: 0.87, 0.92), respectively, with an AUC of 0.94.
    • For early-stage HCC, pooled sensitivity was 0.83 (95% CI: 0.78, 0.87) and specificity was 0.81 (95% CI: 0.78, 0.83), with an AUC of 0.90.
    • The GALAD model demonstrated high sensitivity and specificity for early-stage HCC.

    Conclusions:

    • The GALAD model exhibits excellent diagnostic performance for both early-stage and all-stage HCC.
    • The model maintains high sensitivity and specificity in detecting early-stage HCC.
    • The GALAD model is suitable for screening early-stage canceration in patients with chronic liver disease.
    logistic models